These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35112482)

  • 1. Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study.
    Gorai S; Junghare V; Kundu K; Gharui S; Kumar M; Patro BS; Nayak SK; Hazra S; Mula S
    ChemMedChem; 2022 Apr; 17(8):e202100782. PubMed ID: 35112482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
    Tatar G; Salmanli M; Dogru Y; Tuzuner T
    J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.
    Jo S; Kim S; Kim DY; Kim MS; Shin DH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1539-1544. PubMed ID: 32746637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.
    Kumar V; Kar S; De P; Roy K; Leszczynski J
    SAR QSAR Environ Res; 2022 May; 33(5):357-386. PubMed ID: 35380087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme.
    Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA
    Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.
    Jo S; Kim H; Kim S; Shin DH; Kim MS
    Chem Biol Drug Des; 2019 Dec; 94(6):2023-2030. PubMed ID: 31436895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
    Rehman MT; AlAjmi MF; Hussain A
    Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An
    Mishra B; Ballaney P; Saha G; Shinde A; Banerjee S; Thimmakondu VS; Aduri R
    J Biomol Struct Dyn; 2023 May; 41(8):3167-3186. PubMed ID: 35261325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Flavonoids: A Natural Scaffold with Prospects as Phytomedicines against SARS-CoV2.
    Saha C; Naskar R; Chakraborty S
    Mini Rev Med Chem; 2024; 24(1):39-59. PubMed ID: 37138419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
    Ishola AA; Adedirin O; Joshi T; Chandra S
    Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies.
    Patil VR; Dhote AM; Patil R; Amnerkar ND; Lokwani DK; Ugale VG; Charbe NB; Firke SD; Chaudhari P; Shah SK; Mehta CH; Nayak UY; Khadse SC
    J Biomol Struct Dyn; 2023; 41(22):13168-13179. PubMed ID: 36757134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.